| In millions, except per share items | Jun-30-23 | Jun-30-22 |
| | 10-Q | 10-Q |
| Revenues: |
| Clinical Services | 726 | 723 |
| Enabling Services | 67 | 70 |
| Other | 155 | 146 |
| Intersegment eliminations | 2 | 4 |
| Total revenues | 793 | 793 |
| Revenue growth [+] | 0.0% | |
| Clinical Services | 0.4% | |
| Enabling Services | -4.2% | |
| Other | 5.8% | |
| Intersegment eliminations | -51.4% | |
| Cost of goods sold | 649 | 614 |
| Gross profit | 144 | 179 |
| Gross margin | 18.1% | 22.5% |
| Selling, general and administrative | 81 | 71 |
| EBITDA [+] | 63 | 108 |
| EBITDA growth | -41.6% | |
| EBITDA margin | 7.9% | 13.6% |
| Depreciation | 9 | -9 |
| EBITA | 54 | 116 |
| EBITA margin | 6.8% | 14.6% |
| Amortization of intangibles | 16 | 32 |
| EBIT [+] | 38 | 84 |
| EBIT growth | -55.2% | |
| EBIT margin | 4.8% | 10.6% |
| Non-recurring items | 4 | 13 |
| Interest expense | 1 | |
| Interest expense | 1 | |
| Other income (expense), net [+] | 6 | 12 |
| Gain (loss) on foreign currency transactions | 5 | 12 |
| Other | 0 | 0 |
| Pre-tax income | 39 | 84 |
| Income taxes | 11 | 17 |
| Tax rate | 27.2% | 20.6% |
| Net income | 28 | 66 |
| Net margin | 3.6% | 8.4% |
| |
| Basic EPS [+] | $0.32 | $0.75 |
| Growth | -57.4% | |
| Diluted EPS [+] | $0.32 | $0.75 |
| Growth | -57.4% | |
| |
| Shares outstanding (basic) | 89 | 89 |
| Growth | 0.0% | |
| Shares outstanding (diluted) | 89 | 89 |
| Growth | 0.0% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |